NCT00297856View on ClinicalTrials.gov

Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

CompletedOBSERVATIONAL

Enrollment

10,000

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

DiphtheriaTetanusAcellular Pertussis

Interventions

BIOLOGICAL

Boostrix®

Single dose

BIOLOGICAL

Td (Tetanus diphtheria) vaccine

Single dose

Trial Locations (1)

94612

GSK Investigational Site, Oakland

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00297856 - Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine | Biotech Hunter | Biotech Hunter